WITHDRAWN: Non-viral vectors based on cationic niosomes as efficient gene delivery vehicles to central nervous system cells into the brain

Author(s):  
Mohamed Mashal ◽  
Noha Attia ◽  
Cristina Soto-Sánchez ◽  
Gema Martínez-Navarrete ◽  
Eduardo Fernández ◽  
...  
2018 ◽  
Vol 552 (1-2) ◽  
pp. 48-55 ◽  
Author(s):  
Mohamed Mashal ◽  
Noha Attia ◽  
Cristina Soto-Sánchez ◽  
Gema Martínez-Navarrete ◽  
Eduardo Fernández ◽  
...  

2012 ◽  
Vol 48 (2) ◽  
pp. 179-188 ◽  
Author(s):  
Thomas B. Lentz ◽  
Steven J. Gray ◽  
R. Jude Samulski

2019 ◽  
Vol 93 (11) ◽  
Author(s):  
Blake H. Albright ◽  
Katherine E. Simon ◽  
Minakshi Pillai ◽  
Garth W. Devlin ◽  
Aravind Asokan

ABSTRACT Central nervous system (CNS) transduction by systemically administered recombinant adeno-associated viral (AAV) vectors requires crossing the blood-brain barrier (BBB). We recently mapped a structural footprint on the AAVrh.10 capsid, which, when grafted onto the AAV1 capsid (AAV1RX), enables viral transport across the BBB; however, the underlying mechanisms remain unknown. Here, we establish through structural modeling that this footprint overlaps in part the sialic acid (SIA) footprint on AAV1. We hypothesized that altered SIA-capsid interactions may influence the ability of AAV1RX to transduce the CNS. Using AAV1 variants with altered SIA footprints, we map functional attributes of these capsids to their relative SIA dependence. Specifically, capsids with ablated SIA binding can penetrate and transduce the CNS with low to moderate efficiency. In contrast, AAV1 shows strong SIA dependency and does not transduce the CNS after systemic administration and, instead, transduces the vasculature and the liver. The AAV1RX variant, which shows an intermediate SIA binding phenotype, effectively enters the brain parenchyma and transduces neurons at levels comparable to the level of AAVrh.10. In corollary, the reciprocal swap of the AAV1RX footprint onto AAVrh.10 (AAVRX1) attenuated CNS transduction relative to that of AAVrh.10. We conclude that the composition of residues within the capsid variable region 1 (VR1) of AAV1 and AAVrh.10 profoundly influences tropism, with altered SIA interactions playing a partial role in this phenotype. Further, we postulate a Goldilocks model, wherein optimal glycan interactions can influence the CNS transduction profile of AAV capsids. IMPORTANCE Understanding how viruses cross the blood-brain barrier can provide insight into new approaches to block infection by pathogens or the ability to exploit these pathways for designing new recombinant viral vectors for gene therapy. In this regard, modulation of virus-carbohydrate interactions by mutating the virion shell can influence the ability of recombinant viruses to cross the vascular barrier, enter the brain, and enable efficient gene transfer to neurons.


2016 ◽  
Vol 55 (2) ◽  
pp. 280-287 ◽  
Author(s):  
Mehmet Isik ◽  
Mireia Agirre ◽  
Jon Zarate ◽  
Gustavo Puras ◽  
David Mecerreyes ◽  
...  

Neurosurgery ◽  
2003 ◽  
Vol 52 (2) ◽  
pp. 402-413 ◽  
Author(s):  
Arun Paul Amar ◽  
Berislav V. Zlokovic ◽  
Michael L.J. Apuzzo

Abstract THE AMALGAM OF molecular biology and neurosurgery offers immense promise for neurorestoration and the management of neurodegenerative deficiencies, developmental disorders, neoplasms, stroke, and trauma. This article summarizes present strategies for and impediments to gene therapy and stem cell therapy of the central nervous system and advances the concept of a potential new approach, namely endovascular restorative neurosurgery. The objectives of gene transfer to the central nervous system are efficient transfection of host cells, selective sustained expression of the transgene, and lack of toxicity or immune excitation. The requisite elements of this process are the identification of candidate diseases, the construction of vehicles for gene transfer, regulated expression, and physical delivery. In the selection of target disorders, the underlying genetic events to be overcome, as well as their spatial and temporal distributions, must be considered. These factors determine the requirements for the physical dispersal of the transgene, the duration of transgene expression, and the quantity of transgene product needed to abrogate the disease phenotype. Vehicles for conveying the transgene to the central nervous system include viral vectors (retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, and herpes simplex virus), liposomes, and genetically engineered cells, including neural stem cells. Delivery of the transgene into the brain presents several challenges, including limited and potentially risky access through the cranium, sensitivity to volumetric changes, restricted diffusion, and the blood-brain barrier. Genetic or cellular therapeutic agents may be injected directly into the brain parenchyma (via stereotaxy or craniotomy), into the cerebrospinal fluid (in the ventricles or cisterns), or into the bloodstream (intravenously or intra-arterially). The advantages of the endovascular route include the potential for widespread distribution, the ability to deliver large volumes, limited perturbation of neural tissue, and the feasibility of repeated administration.


2013 ◽  
Vol 5 (12) ◽  
pp. 5648-5658 ◽  
Author(s):  
Hee-Kwon Kim ◽  
David H. Thompson ◽  
Ho Seong Jang ◽  
Yong Jin Chung ◽  
Jeroen Van den Bossche

Sign in / Sign up

Export Citation Format

Share Document